Addex Therapeutics ( (CH:ADXN) ) just unveiled an announcement.
Addex Therapeutics reported its full-year 2024 financial results, highlighting significant progress in its clinical development programs and strategic partnerships. The company launched Neurosterix with Perceptive Advisors, raising $65 million to advance its preclinical portfolio, and regained rights to its mGlu2 PAM asset, ADX71149. Despite a net loss from continuing operations, Addex achieved a net profit of CHF 7.1 million, primarily due to gains from discontinued operations following the sale of part of its business.
More about Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders. The company is advancing several drug candidates, including dipraglurant for brain injury recovery and a GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions.
Average Trading Volume: 100
Current Market Cap: $34.8M
For an in-depth examination of ADXN stock, go to TipRanks’ Stock Analysis page.